Cargando…
Difficult-to-treat-pediatric Crohn’s disease: focus on adalimumab
Adalimumab is a fully humanized anti-tumor necrosis factor alpha monoclonal antibody that was recently granted regulatory approval in the USA for the treatment of moderate to severe Crohn’s disease (CD) in children. Like infliximab, the first biologic agent used to treat pediatric CD, regulatory app...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683269/ https://www.ncbi.nlm.nih.gov/pubmed/29388607 http://dx.doi.org/10.2147/PHMT.S40948 |
_version_ | 1783278247267532800 |
---|---|
author | Zeisler, Bella Hyams, Jeffrey S |
author_facet | Zeisler, Bella Hyams, Jeffrey S |
author_sort | Zeisler, Bella |
collection | PubMed |
description | Adalimumab is a fully humanized anti-tumor necrosis factor alpha monoclonal antibody that was recently granted regulatory approval in the USA for the treatment of moderate to severe Crohn’s disease (CD) in children. Like infliximab, the first biologic agent used to treat pediatric CD, regulatory approval was secured many years following approval for adults. The long delay between adult and pediatric approval has led to many years of off-label use of adalimumab, although it is anticipated that the use of adalimumab may further increase with official regulatory approval. To date, pediatric literature on the use of adalimumab for treatment of CD is limited, and pediatric practitioners have mostly extrapolated from research and experience provided by the adult literature. The aim of this paper is to review the literature regarding adalimumab for the treatment of pediatric CD, and includes a review of landmark adult studies as well as the pivotal pediatric study that facilitated regulatory approval. We also discuss the role of anti-tumor necrosis factor alpha agents including adalimumab in the current treatment paradigm for pediatric CD. |
format | Online Article Text |
id | pubmed-5683269 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-56832692018-01-31 Difficult-to-treat-pediatric Crohn’s disease: focus on adalimumab Zeisler, Bella Hyams, Jeffrey S Pediatric Health Med Ther Review Adalimumab is a fully humanized anti-tumor necrosis factor alpha monoclonal antibody that was recently granted regulatory approval in the USA for the treatment of moderate to severe Crohn’s disease (CD) in children. Like infliximab, the first biologic agent used to treat pediatric CD, regulatory approval was secured many years following approval for adults. The long delay between adult and pediatric approval has led to many years of off-label use of adalimumab, although it is anticipated that the use of adalimumab may further increase with official regulatory approval. To date, pediatric literature on the use of adalimumab for treatment of CD is limited, and pediatric practitioners have mostly extrapolated from research and experience provided by the adult literature. The aim of this paper is to review the literature regarding adalimumab for the treatment of pediatric CD, and includes a review of landmark adult studies as well as the pivotal pediatric study that facilitated regulatory approval. We also discuss the role of anti-tumor necrosis factor alpha agents including adalimumab in the current treatment paradigm for pediatric CD. Dove Medical Press 2015-04-28 /pmc/articles/PMC5683269/ /pubmed/29388607 http://dx.doi.org/10.2147/PHMT.S40948 Text en © 2015 Zeisler and Hyams. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. |
spellingShingle | Review Zeisler, Bella Hyams, Jeffrey S Difficult-to-treat-pediatric Crohn’s disease: focus on adalimumab |
title | Difficult-to-treat-pediatric Crohn’s disease: focus on adalimumab |
title_full | Difficult-to-treat-pediatric Crohn’s disease: focus on adalimumab |
title_fullStr | Difficult-to-treat-pediatric Crohn’s disease: focus on adalimumab |
title_full_unstemmed | Difficult-to-treat-pediatric Crohn’s disease: focus on adalimumab |
title_short | Difficult-to-treat-pediatric Crohn’s disease: focus on adalimumab |
title_sort | difficult-to-treat-pediatric crohn’s disease: focus on adalimumab |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683269/ https://www.ncbi.nlm.nih.gov/pubmed/29388607 http://dx.doi.org/10.2147/PHMT.S40948 |
work_keys_str_mv | AT zeislerbella difficulttotreatpediatriccrohnsdiseasefocusonadalimumab AT hyamsjeffreys difficulttotreatpediatriccrohnsdiseasefocusonadalimumab |